The Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 pipeline drugs market research report outlays comprehensive information on the Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology, and Immunology which include the indications Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Autoimmune Disorders. It also reviews key players involved in Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 targeted therapeutics development with respective active and dormant or discontinued products.

The Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 pipeline targets constitutes close to 17 molecules. Out of which, approximately 13 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 4, 1, 5, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 3 molecule.

Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 overview

Mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a caspase-like protease that plays a role in BCL10-induced activation of NF-kappaB. The protein is a component of the CARMA1-BCL10-MALT1 (CBM) signalosome that triggers NF-kappaB signaling and lymphoctye activation following antigen-receptor stimulation. Mutations in this gene result in immunodeficiency 12 (IMD12). This gene has been found to be recurrently rearranged in chromosomal translocations with other genes in mucosa-associated lymphoid tissue lymphomas.

For a complete picture of Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.